New Prostate Cancer Drugs are Expensive Because of Government-Granted Patent Monopolies

Print
Tuesday, 28 June 2011 04:41
That point would have been worth making in an article about new drugs approved by the Food and Drug Administration for treating prostrate cancer. According to the article, these drug costs can cost up to $8,000 a month. If the drugs were sold in a free market without patent protection, they would almost certainly sell for less than $100 a month. It would have been worth noting this cost of the patent system for financing prescription drug research.